The National Comprehensive Cancer Network (NCCN)
recently updated the NCCN Clinical Practice Guidelines for Oncology™
for Ovarian Cancer to reflect the addition of two preferred combination
regimens for a specific cohort of patients based on data from recent
clinical research studies.
“Although finding effective screening tools remains
a priority, new treatment options for women with ovarian cancer such as
the ones outlined in the updated NCCN Guidelines, remains imperative to
making steady progress against the disease.”
Key updates to the NCCN Guidelines include the addition of carboplatin
(Paraplatin®, Bristol-Myers Squibb)/weekly paclitaxel (Taxol®,
Bristol-Myers Squibb) and carboplatin/liposomal doxorubicin (Doxil®,
Centocor Ortho Biotech) for cytotoxic therapy for patients with
platinum-sensitive epithelial ovarian cancer, fallopian tube cancer, or
primary peritoneal cancer that has recurred.
These modifications made to the NCCN Guidelines for Ovarian Cancer are
based on results from recent studies in The
Lancet and The
Journal of Clinical Oncology demonstrating that both combination
regimens improved median progression-free survival in women with
specific types of recurring ovarian cancer as compared to conventional
regimens. In addition, the carboplatin/weekly paclitaxel regimen
improved overall survival.